Novo Holdings to Acquire Catalent
Catalent and Novo Holdings have entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis.
Showing Results 111-120 Of 76 For Italy
Catalent Acquires Facility in Oxfordshire to Expand Biologics Capabilities in the UK and Across Europe
Catalent today announced the acquisition from Vaccine Manufacturing and Innovation Centre UK Limited of a biologics development and manufacturing facility currently under construction near Oxford, U.K.
Catalent Biologics Completes Madison Facility Expansion to Double Clinical and Commercial Drug Substance Capacity
Catalent has completed the expansion of two new suites at its biologics drug substance development and manufacturing facility in Madison, Wisconsin, and has now commenced work on customer programs.
Moderna and Catalent Announce Long-Term Strategic Collaboration for Dedicated Vial Filling of Moderna’s COVID-19 Vaccine and Clinical Portfolio
Moderna and Catalent today announced the expansion of their strategic partnership to dedicate a new high-speed vial filling line for the manufacture of the Moderna COVID-19 Vaccine at Catalent’s facility in Bloomington, Indiana.
Catalent VP Of Global Operations Wins Program Director Of The Year Award
Catalent VP Of Global Operations Wins Program Director Of The Year Award. Somerset, N.J. – January 23, 2015 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies a…